Efalizumab in the Treatment of Alopecia, Phase II

Status Withdrawn

Clinical Trial Summary

Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.

Clinical Trial Description

This is a Phase II trial (single-center, open-label, prospective study) where subjects with severe forms of alopecia areata, namely alopecia totalis, universalis, and severe ophiasis, will be treated with efalizumab (Raptiva), a humanized monoclonal anti-CD11a antibody that reversibly inhibits T cell activation and migration, weekly for 48 weeks. We will assess for effect on hair and body re-growth as well as record any serious adverse events such as serious infections, thrombocytopenia, development of malignancy, and severe arthralgias to monitor for safety outcome data. Subjects will have regular physical examinations and laboratory studies throughout the study, as well as telephone interviews. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00746980
Study type	Interventional
Source	Northwestern University
Contact
Status	Withdrawn
Phase	Phase 2
Start date	August 2008
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02812342` - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2
Recruiting	`NCT04011748` - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Phase 2
Withdrawn	`NCT03532958` - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata	Phase 2
Completed	`NCT05098600` - The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Active, not recruiting	`NCT00069589` - Alopecia Areata Registry
Completed	`NCT06278402` - Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.	Phase 3
Completed	`NCT01167946` - Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata	Phase 4
Recruiting	`NCT06283316` - Systemic Treatments for Alopecia Areata Registry
Terminated	`NCT03759340` - ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)	Phase 2
Completed	`NCT02312882` - Tofacitinib for the Treatment of Alopecia Areata and Its Variants	N/A
Active, not recruiting	`NCT05589610` - Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata	Phase 2
Withdrawn	`NCT04238091` - Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata	Phase 2
Completed	`NCT03551821` - Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata	Phase 2